Home > News > BioAlliance Pharma Announces Preliminary Results
June 30th, 2006
BioAlliance Pharma Announces Preliminary Results
Abstract:
BioAlliance Pharma SA (Paris:BIO) announced today the presentation of preliminary results from its Doxorubicin Transdrug(R) Phase I/II clinical trial for primary liver cancer. "These results are also extremely positive because of their encouraging implications for the future application of our Transdrug(R) nanotechnology platform."
Source:
businesswire
Bookmark:
| Related News Press |
Possible Futures
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||